Results 141 to 150 of about 201,272 (267)
Gut microbiota‐related modulation of immune mechanisms in post‐infarction remodelling and heart failure
ESC Heart Failure, Volume 12, Issue 2, Page 942-954, April 2025.Abstract
The immune system has long been recognized as a key driver in the progression of heart failure (HF). However, clinical trials targeting immune effectors have consistently failed to improve patient outcome across different HF aetiologies. The activation of the immune system in HF is complex, involving a broad network of pro‐inflammatory and ...Johann Roessler, Friederike Zimmermann, Bettina Heidecker, Ulf Landmesser, Arash Haghikia +4 morewiley +1 more sourceStandard-Dose Tenecteplase vs Low-Dose Alteplase for Acute Ischemic Stroke From Large-Vessel Occlusion: A Randomized Clinical Trial.
JAMA NeurolInoue M, Hirano T, Fukuda-Doi M, Kawano H, Tanaka K, Sakai N, Koga M, Iwasaki K, Yoshie T, Kamogawa N, Ihara M, Ohta T, Chin M, Kimura N, Kimura K, Tateishi Y, Terasaki T, Hatano T, Kuwashiro T, Yoshimura S, Ueda T, Nagata E, Nagakane Y, Takahashi S, Miyashita F, Sonoda K, Fukuda K, Tanaka K, Une Y, Kobari S, Nagao T, Sasaki M, Yamamoto H, Toyoda K, T-FLAVOR trial Investigators. +34 moreeuropepmc +1 more sourceMeta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes
ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.Abstract
Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip +7 morewiley +1 more sourcePersonalized Blood Pressure Targeting After Endovascular Therapy for Acute Ischemic Stroke: A Randomized Clinical Trial.
JAMA NeurolCamps-Renom P, Guasch-Jiménez M, Álvarez-Cienfuegos J, López-Hernández N, Rodríguez-Campello A, Tejada-Meza H, López-Mesonero L, Albert-Lacal L, Freijo-Guerrero MM, Tarruella-Hernández D, Flores A, Cabezas-Rodríguez JA, Fernández-Vidal JM, Martínez-Domeño A, Pérez de la Ossa N, Ramos-Pachón A, Aguilera-Simón A, Marín R, Ezcurra-Díaz G, Lambea-Gil Á, Silva Y, Corona-García DJ, Giralt-Steinhauer E, Marta-Moreno J, Vizcaya-Gaona JA, Sanz-Monllor A, Luna A, López Morales M, Ustrell X, Moniche F, Solà-Roca J, Wang X, Anderson CS, Prats-Sánchez L, Martí-Fàbregas J, HOPE Study Group. +35 moreeuropepmc +1 more sourceNeutrophil-Membrane Biomimetic Hollow Mesoporous Silica Nanoparticles for Targeted Delivery of Imperatorin to Alleviate Cerebral Ischemia-Reperfusion Injury via Nrf2/ARE/Keap1 Pathway. [PDF]
Int J NanomedicineChen F, Jiang H, Song X, Wang J, Ma X, Zhou Q, Mamun AA, Li L, Zhou Y, Xu H, Wang S. +10 moreeuropepmc +1 more sourceA contemporary simple risk score for prediction of severe acute kidney injury after heart transplantation
ESC Heart Failure, Volume 12, Issue 2, Page 1166-1175, April 2025.A contemporary simple risk score for prediction of severe AKI after HT. Abstract Background
The aim of this study was to develop a simple risk score to estimate severe acute kidney injury (AKI) risk based on a large contemporary heart transplantation (HT) cohort.Shuangshuang Zhu, Weihua Qiao, Yixuan Wang, Ying Zhou, Yin Xu, Shijie Wang, Tian Xia, Guohua Wang, Si Chen, Jiawei Shi, Nianguo Dong +10 morewiley +1 more sourceInterventional therapies for chronic heart failure: An overview of recent developments
ESC Heart Failure, Volume 12, Issue 2, Page 1081-1094, April 2025.Abstract
Heart failure (HF), the final manifestation of most cardiovascular diseases, has become a major global health concern, affecting millions of individuals. Despite basic drug treatments, patients present with high morbidity and mortality rates. However, recent advancements in interventional therapy have shown promising results in improving the ...Bingchen Guo, Si Shi, Yutong Guo, Jie Xiong, Bo Wang, Zengxiang Dong, Dianyu Gao, Yingfeng Tu +7 morewiley +1 more sourceTransendocardial injection of expanded autologous CD34+ cells after myocardial infarction: Design of the EXCELLENT trial
ESC Heart Failure, Volume 12, Issue 2, Page 1455-1463, April 2025.Abstract Aims
The extent of irreversible cardiomyocyte necrosis after acute myocardial infarction (AMI) is a major determinant of residual left ventricular (LV) function and clinical outcome. Cell therapy based on CD34+ cells has emerged as an option to help repair the myocardium and to improve outcomes.Jerome Roncalli, François Roubille, Nicolas Meyer, Giulio Pompilio, Lionel Leroux, Philippe Henon, Guillaume Trebuchet, Anthony Criquet, Matthieu de Kalbermatten, Eric Saloux, Alain Manrique, Pierre‐Yves Marie, Deepak L. Bhatt, Scott D. Solomon, Gilles Montalescot, David E. Newby, Faiez Zannad, on behalf of
the EXCELLENT Trial Investigators +17 morewiley +1 more sourceMetabolic abnormalities and reprogramming in cats with naturally occurring hypertrophic cardiomyopathy
ESC Heart Failure, Volume 12, Issue 2, Page 1256-1270, April 2025.Abstract Background and aims
The heart is a metabolic organ rich in mitochondria. The failing heart reprograms to utilize different energy substrates, which increase its oxygen consumption. These adaptive changes contribute to increased oxidative stress.Qinghong Li, Max Homilius, Erin Achilles, Laura K. Massey, Victoria Convey, Åsa Ohlsson, Ingrid Ljungvall, Jens Häggström, Brittany Vester Boler, Pascal Steiner, Sharlene Day, Calum A. MacRae, Mark A. Oyama +12 morewiley +1 more source